Last updated: 20 July 2019 at 6:56pm EST

Peter Dansky Net Worth




The estimated Net Worth of Peter Dansky is at least $171 mil dollars as of 14 June 2010. Peter Dansky owns over 2,700 units of Atyr Pharma Inc stock worth over $8,560 and over the last 16 years Peter sold LIFE stock worth over $162,232.

Peter Dansky LIFE stock SEC Form 4 insiders trading

Peter has made over 6 trades of the Atyr Pharma Inc stock since 2009, according to the Form 4 filled with the SEC. Most recently Peter exercised 2,700 units of LIFE stock worth $60,021 on 14 June 2010.

The largest trade Peter's ever made was exercising 20,875 units of Atyr Pharma Inc stock on 17 November 2009 worth over $831,034. On average, Peter trades about 3,848 units every 44 days since 2008. As of 14 June 2010 Peter still owns at least 4,505 units of Atyr Pharma Inc stock.

You can see the complete history of Peter Dansky stock trades at the bottom of the page.



What's Peter Dansky's mailing address?

Peter's mailing address filed with the SEC is 5791 VAN ALLEN WAY, , CARLSBAD, CA, 92008.

Insiders trading at Atyr Pharma Inc

Over the last 16 years, insiders at Atyr Pharma Inc have traded over $27,288,922 worth of Atyr Pharma Inc stock and bought 966,653 units worth $5,761,237 . The most active insiders traders include James C Blair, Gregory T Lucier, eCraig J Mundie. On average, Atyr Pharma Inc executives and independent directors trade stock every 22 days with the average trade being worth of $34,257. The most recent stock trade was executed by Jill Marie Broadfoot on 31 May 2024, trading 5,000 units of LIFE stock currently worth $8,950.



What does Atyr Pharma Inc do?

atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd. to protect this pipeline, atyr built an intellectual property estate comprising 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by atyr. atyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation



Complete history of Peter Dansky stock trades at Atyr Pharma Inc

Acionista maioritário
Trans.
Transação
Preço total
Peter Dansky
Pres e Molecular Biology Sys
Exercício de opção $60,021
14 Jun 2010
Peter Dansky
Pres e Molecular Biology Sys
Exercício de opção $133,380
12 May 2010
Peter Dansky
Pres e Molecular Biology Sys
Exercício de opção $28,899
7 May 2010
Peter Dansky
Pres e Molecular Biology Sys
Exercício de opção $133,380
10 Mar 2010
Peter Dansky
Pres e Molecular Biology Sys
Exercício de opção $831,034
17 Nov 2009
Peter Dansky
Pres e Molecular Biology Sys
Venda $162,232
18 Feb 2009


Atyr Pharma Inc executives and stock owners

Atyr Pharma Inc executives and other stock owners filed with the SEC include: